Cargando…
GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
INTRODUCTION: The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is evolving and expanding. This retrospective database study evaluated recent real-world treatment and dosing patterns of patients with type 2 diabetes (T2D) initiating GLP-1 RAs in Belgium (BE), France (FR), Germany (DE), I...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531601/ https://www.ncbi.nlm.nih.gov/pubmed/31028689 http://dx.doi.org/10.1007/s13300-019-0615-5 |
_version_ | 1783420863075319808 |
---|---|
author | Divino, Victoria Boye, Kristina S. Lebrec, Jeremie DeKoven, Mitch Norrbacka, Kirsi |
author_facet | Divino, Victoria Boye, Kristina S. Lebrec, Jeremie DeKoven, Mitch Norrbacka, Kirsi |
author_sort | Divino, Victoria |
collection | PubMed |
description | INTRODUCTION: The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is evolving and expanding. This retrospective database study evaluated recent real-world treatment and dosing patterns of patients with type 2 diabetes (T2D) initiating GLP-1 RAs in Belgium (BE), France (FR), Germany (DE), Italy (IT), the Netherlands (NL), and Canada (CA). METHODS: Adult T2D patients initiating GLP-1 RA therapy (dulaglutide [DULA], exenatide twice daily [exBID], exenatide once weekly [exQW], liraglutide [LIRA], or lixisenatide [LIXI]) from 2015 to 2016 were identified using the IQVIA (IQVIA, Durham, NC, and Danbury, CT, USA) Real-World Data Adjudicated Pharmacy Claims. The therapy initiation date was termed the ‘index date.’ Eligible patients had ≥ 180 days pre-index and ≥ 360 days post-index. Persistence (until discontinuation or switch) was evaluated over the variable follow-up using Kaplan–Meier (KM) survival analysis. Average daily dose (ADD) was calculated until discontinuation or switch. RESULTS: A total of 34,649 DULA, 3616 exBID, 11,138 exQW, 48,317 LIRA, and 2,204 LIXI patients were included in the analysis (34.9–63.2% female; median age range 53–62 years; median follow-up 16–30 months). Proportion persistent at 1-year post-index was 36.8–67.2% for DULA, 5.9–44.4% for exBID, 24.7–44.2% for exQW, 22.2–57.5% for LIRA, and 15.5–40.0% for LIXI. Median time persistent (days) was 245–381 for DULA, 62–243 for exBID, 121–319 for exQW, 103–507 for LIRA, and 99–203 for LIXI. Mean ADD was 13.21–20.43 µg for exBID, 1.44–1.68 mg for LIRA, and 19.88–20.54 µg for LIXI. Mean average weekly dose (AWD) ranged from 2.03 to 2.14 mg for exQW. Mean AWD for DULA was 1.25 mg in Canada and ranged from 1.43 to 1.53 mg in the other countries. CONCLUSION: Across six countries, persistence was highest among DULA patients and generally lowest among exBID patients. ADD/AWD for all GLP-1 RAs was in line with the recommended label. Longer-term data would be useful to obtain a better understanding of GLP-1 RA treatment patterns over time. FUNDING: Eli Lilly and Company, Indianapolis, IN, USA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-019-0615-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6531601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-65316012019-06-07 GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data Divino, Victoria Boye, Kristina S. Lebrec, Jeremie DeKoven, Mitch Norrbacka, Kirsi Diabetes Ther Original Research INTRODUCTION: The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is evolving and expanding. This retrospective database study evaluated recent real-world treatment and dosing patterns of patients with type 2 diabetes (T2D) initiating GLP-1 RAs in Belgium (BE), France (FR), Germany (DE), Italy (IT), the Netherlands (NL), and Canada (CA). METHODS: Adult T2D patients initiating GLP-1 RA therapy (dulaglutide [DULA], exenatide twice daily [exBID], exenatide once weekly [exQW], liraglutide [LIRA], or lixisenatide [LIXI]) from 2015 to 2016 were identified using the IQVIA (IQVIA, Durham, NC, and Danbury, CT, USA) Real-World Data Adjudicated Pharmacy Claims. The therapy initiation date was termed the ‘index date.’ Eligible patients had ≥ 180 days pre-index and ≥ 360 days post-index. Persistence (until discontinuation or switch) was evaluated over the variable follow-up using Kaplan–Meier (KM) survival analysis. Average daily dose (ADD) was calculated until discontinuation or switch. RESULTS: A total of 34,649 DULA, 3616 exBID, 11,138 exQW, 48,317 LIRA, and 2,204 LIXI patients were included in the analysis (34.9–63.2% female; median age range 53–62 years; median follow-up 16–30 months). Proportion persistent at 1-year post-index was 36.8–67.2% for DULA, 5.9–44.4% for exBID, 24.7–44.2% for exQW, 22.2–57.5% for LIRA, and 15.5–40.0% for LIXI. Median time persistent (days) was 245–381 for DULA, 62–243 for exBID, 121–319 for exQW, 103–507 for LIRA, and 99–203 for LIXI. Mean ADD was 13.21–20.43 µg for exBID, 1.44–1.68 mg for LIRA, and 19.88–20.54 µg for LIXI. Mean average weekly dose (AWD) ranged from 2.03 to 2.14 mg for exQW. Mean AWD for DULA was 1.25 mg in Canada and ranged from 1.43 to 1.53 mg in the other countries. CONCLUSION: Across six countries, persistence was highest among DULA patients and generally lowest among exBID patients. ADD/AWD for all GLP-1 RAs was in line with the recommended label. Longer-term data would be useful to obtain a better understanding of GLP-1 RA treatment patterns over time. FUNDING: Eli Lilly and Company, Indianapolis, IN, USA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-019-0615-5) contains supplementary material, which is available to authorized users. Springer Healthcare 2019-04-26 2019-06 /pmc/articles/PMC6531601/ /pubmed/31028689 http://dx.doi.org/10.1007/s13300-019-0615-5 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Divino, Victoria Boye, Kristina S. Lebrec, Jeremie DeKoven, Mitch Norrbacka, Kirsi GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data |
title | GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data |
title_full | GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data |
title_fullStr | GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data |
title_full_unstemmed | GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data |
title_short | GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data |
title_sort | glp-1 ra treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531601/ https://www.ncbi.nlm.nih.gov/pubmed/31028689 http://dx.doi.org/10.1007/s13300-019-0615-5 |
work_keys_str_mv | AT divinovictoria glp1ratreatmentanddosingpatternsamongtype2diabetespatientsinsixcountriesaretrospectiveanalysisofpharmacyclaimsdata AT boyekristinas glp1ratreatmentanddosingpatternsamongtype2diabetespatientsinsixcountriesaretrospectiveanalysisofpharmacyclaimsdata AT lebrecjeremie glp1ratreatmentanddosingpatternsamongtype2diabetespatientsinsixcountriesaretrospectiveanalysisofpharmacyclaimsdata AT dekovenmitch glp1ratreatmentanddosingpatternsamongtype2diabetespatientsinsixcountriesaretrospectiveanalysisofpharmacyclaimsdata AT norrbackakirsi glp1ratreatmentanddosingpatternsamongtype2diabetespatientsinsixcountriesaretrospectiveanalysisofpharmacyclaimsdata |